A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2009-05-12

AUTHORS

N Starling, A Okines, D Cunningham, W Allum, A Wotherspoon, M Benson, J Thompson, J Thomas, G Brown, A Riddell, F Stavridi, S Ashley, J Oates, I Chau

ABSTRACT

Preoperative cisplatin/fluorouracil is used for the treatment of localised oesophageal carcinoma. This phase II study aimed to assess the efficacy and safety of administering preoperative epirubicin/cisplatin/capecitabine (ECX). Patients with stage II or III oesophageal/gastro-oesophageal junctional adenocarcinoma from one institution received 4 cycles of ECX (epirubicin 50 mg m−2 day 1, cisplatin 60 mg m−2 day 1, capecitabine 625 mg m−2 b.i.d. daily) followed by surgery. The primary end point was the pathological complete response (pCR) rate based on a Simon two-stage design. Secondary end points included overall and progression-free survival (OS/PFS). Thirty-four patients were recruited: median age 60 years (range 41–81), 91% male, 97% PS 0/1, 80% T3, 68% N1. Thirty-one patients completed four ECX cycles. Grade 3/4 toxicities ⩾5% included neutropenia (62%), hand–foot syndrome (15%) and nausea/vomiting (9%). Thirteen out of 28 (46%) evaluable patients responded to chemotherapy by EUS (⩾30% reduction in maximal tumour thickness). Twenty-six out of 34 (76%) patients underwent resection (R0=73%, R1=27%). Post-operatively, two patients died within 60 days of surgery. The pCR rate was 5.9% (95% CI 0–14%) in the intent-to-treat population. According to the statistical design, this prompted early study termination. However, with a median follow-up of 34 months the median OS and 1- and 2-year survival rates were 17 months, 67 and 39% respectively. Median PFS was 13 months. Of the 14 relapsed patients, 10 presented with distant metastases. Preoperative ECX is feasible and well tolerated. Although associated with a low pCR rate, survival with ECX was comparable with published studies suggesting that pCR may not correlate with satisfactory outcome from preoperative chemotherapy for localised oesophageal adenocarcinoma. More... »

PAGES

1725-1730

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bjc.6605070

DOI

http://dx.doi.org/10.1038/sj.bjc.6605070

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1037816320

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19436301


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Capecitabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Epirubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Esophageal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stomach Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Starling", 
        "givenName": "N", 
        "id": "sg:person.01136565472.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136565472.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Okines", 
        "givenName": "A", 
        "id": "sg:person.011120523514.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011120523514.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cunningham", 
        "givenName": "D", 
        "id": "sg:person.01320161130.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Surgery, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Allum", 
        "givenName": "W", 
        "id": "sg:person.01176653021.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176653021.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Histopathology, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Histopathology, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wotherspoon", 
        "givenName": "A", 
        "id": "sg:person.01000107664.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000107664.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Benson", 
        "givenName": "M", 
        "id": "sg:person.01265070333.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265070333.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Surgery, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thompson", 
        "givenName": "J", 
        "id": "sg:person.0761075230.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761075230.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thomas", 
        "givenName": "J", 
        "id": "sg:person.0771664431.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0771664431.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Radiology, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Brown", 
        "givenName": "G", 
        "id": "sg:person.01265153477.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265153477.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Radiology, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Riddell", 
        "givenName": "A", 
        "id": "sg:person.01042675252.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01042675252.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stavridi", 
        "givenName": "F", 
        "id": "sg:person.01111010452.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111010452.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Computing and Statistics, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Computing and Statistics, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ashley", 
        "givenName": "S", 
        "id": "sg:person.01345371112.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01345371112.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Oates", 
        "givenName": "J", 
        "id": "sg:person.01270334576.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270334576.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chau", 
        "givenName": "I", 
        "id": "sg:person.01035560774.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035560774.45"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1741-7015-2-35", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004336180", 
          "https://doi.org/10.1186/1741-7015-2-35"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6602572", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003250351", 
          "https://doi.org/10.1038/sj.bjc.6602572"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6600252", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051559904", 
          "https://doi.org/10.1038/sj.bjc.6600252"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-05-12", 
    "datePublishedReg": "2009-05-12", 
    "description": "Preoperative cisplatin/fluorouracil is used for the treatment of localised oesophageal carcinoma. This phase II study aimed to assess the efficacy and safety of administering preoperative epirubicin/cisplatin/capecitabine (ECX). Patients with stage II or III oesophageal/gastro-oesophageal junctional adenocarcinoma from one institution received 4 cycles of ECX (epirubicin 50\u2009mg\u2009m\u22122 day 1, cisplatin 60\u2009mg\u2009m\u22122 day 1, capecitabine 625\u2009mg\u2009m\u22122 b.i.d. daily) followed by surgery. The primary end point was the pathological complete response (pCR) rate based on a Simon two-stage design. Secondary end points included overall and progression-free survival (OS/PFS). Thirty-four patients were recruited: median age 60 years (range 41\u201381), 91% male, 97% PS 0/1, 80% T3, 68% N1. Thirty-one patients completed four ECX cycles. Grade 3/4 toxicities \u2a7e5% included neutropenia (62%), hand\u2013foot syndrome (15%) and nausea/vomiting (9%). Thirteen out of 28 (46%) evaluable patients responded to chemotherapy by EUS (\u2a7e30% reduction in maximal tumour thickness). Twenty-six out of 34 (76%) patients underwent resection (R0=73%, R1=27%). Post-operatively, two patients died within 60 days of surgery. The pCR rate was 5.9% (95% CI 0\u201314%) in the intent-to-treat population. According to the statistical design, this prompted early study termination. However, with a median follow-up of 34 months the median OS and 1- and 2-year survival rates were 17 months, 67 and 39% respectively. Median PFS was 13 months. Of the 14 relapsed patients, 10 presented with distant metastases. Preoperative ECX is feasible and well tolerated. Although associated with a low pCR rate, survival with ECX was comparable with published studies suggesting that pCR may not correlate with satisfactory outcome from preoperative chemotherapy for localised oesophageal adenocarcinoma.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.bjc.6605070", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "100"
      }
    ], 
    "keywords": [
      "preoperative chemotherapy", 
      "junctional adenocarcinoma", 
      "median age 60 years", 
      "pathological complete response rate", 
      "end point", 
      "cisplatin/fluorouracil", 
      "cisplatin/capecitabine", 
      "Secondary end points", 
      "grade 3/4 toxicities", 
      "hand-foot syndrome", 
      "nausea/vomiting", 
      "early study termination", 
      "phase II study", 
      "primary end point", 
      "complete response rate", 
      "progression-free survival", 
      "phase II trial", 
      "day of surgery", 
      "age 60 years", 
      "PS 0/1", 
      "evaluable patients", 
      "treat population", 
      "median OS", 
      "median PFS", 
      "II study", 
      "pCR rate", 
      "II trial", 
      "oesophageal carcinoma", 
      "distant metastasis", 
      "oesophageal adenocarcinoma", 
      "study termination", 
      "patients", 
      "satisfactory outcome", 
      "response rate", 
      "survival rate", 
      "stage II", 
      "chemotherapy", 
      "adenocarcinoma", 
      "months", 
      "capecitabine", 
      "surgery", 
      "two-stage design", 
      "survival", 
      "neutropenia", 
      "vomiting", 
      "resection", 
      "fluorouracil", 
      "carcinoma", 
      "metastasis", 
      "epirubicin", 
      "syndrome", 
      "EUS", 
      "PFS", 
      "cisplatin", 
      "trials", 
      "efficacy", 
      "rate", 
      "outcomes", 
      "treatment", 
      "ECX", 
      "T3", 
      "males", 
      "study", 
      "toxicity", 
      "days", 
      "safety", 
      "OS", 
      "population", 
      "years", 
      "N1", 
      "termination", 
      "intent", 
      "cycle", 
      "institutions", 
      "point", 
      "design", 
      "statistical design", 
      "Simon"
    ], 
    "name": "A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma", 
    "pagination": "1725-1730", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1037816320"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bjc.6605070"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19436301"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bjc.6605070", 
      "https://app.dimensions.ai/details/publication/pub.1037816320"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:35", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_494.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.bjc.6605070"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605070'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605070'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605070'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605070'


 

This table displays all metadata directly associated to this object as RDF triples.

330 TRIPLES      21 PREDICATES      126 URIs      115 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bjc.6605070 schema:about N0c1b27e5a91543b0ab1a858ab077d394
2 N2108206adfb64d5897d9e15e89077740
3 N2508ae81ae4a4b16b9e177873f8b71e1
4 N2cc05ed3136e441591bf6b85ace5e0d4
5 N30f42e59786941d6a8a101c06738d1f0
6 N3cb7b3f6ed98467681cde4f98eb2634a
7 N48783759dd29455abd8c3a11f3eb0f4a
8 N4959b325254b40d791def4d37e980165
9 N57e1416f04904026ba7026f728e01e5d
10 N5c21635fd0324c67bedfe99de321573e
11 N6252b3982ba3487ca7d5c3ff7c4a396b
12 N6cc7c541206046dcbf6cc4596989e739
13 N7d42851743d64c5ab593aa71b602821d
14 N7e225bc7d6ca49c3b1c39061cb754e5b
15 N84194ba192e44330bb7238cd3189684d
16 N86c28f312af4473cac62de6d1cfed552
17 N920dd36ab3c7429497ee4083bd1492a8
18 Nd59bf7c57b17451292b9c0163f4aba50
19 Ndbbeffd489f44d3290b26b4481c52e98
20 Ne424e6f2881c4acba0fbf11e503f9613
21 anzsrc-for:11
22 anzsrc-for:1112
23 schema:author N36e2411d796b4cb4a5c97ca5fb8ea702
24 schema:citation sg:pub.10.1038/sj.bjc.6600252
25 sg:pub.10.1038/sj.bjc.6602572
26 sg:pub.10.1186/1741-7015-2-35
27 schema:datePublished 2009-05-12
28 schema:datePublishedReg 2009-05-12
29 schema:description Preoperative cisplatin/fluorouracil is used for the treatment of localised oesophageal carcinoma. This phase II study aimed to assess the efficacy and safety of administering preoperative epirubicin/cisplatin/capecitabine (ECX). Patients with stage II or III oesophageal/gastro-oesophageal junctional adenocarcinoma from one institution received 4 cycles of ECX (epirubicin 50 mg m−2 day 1, cisplatin 60 mg m−2 day 1, capecitabine 625 mg m−2 b.i.d. daily) followed by surgery. The primary end point was the pathological complete response (pCR) rate based on a Simon two-stage design. Secondary end points included overall and progression-free survival (OS/PFS). Thirty-four patients were recruited: median age 60 years (range 41–81), 91% male, 97% PS 0/1, 80% T3, 68% N1. Thirty-one patients completed four ECX cycles. Grade 3/4 toxicities ⩾5% included neutropenia (62%), hand–foot syndrome (15%) and nausea/vomiting (9%). Thirteen out of 28 (46%) evaluable patients responded to chemotherapy by EUS (⩾30% reduction in maximal tumour thickness). Twenty-six out of 34 (76%) patients underwent resection (R0=73%, R1=27%). Post-operatively, two patients died within 60 days of surgery. The pCR rate was 5.9% (95% CI 0–14%) in the intent-to-treat population. According to the statistical design, this prompted early study termination. However, with a median follow-up of 34 months the median OS and 1- and 2-year survival rates were 17 months, 67 and 39% respectively. Median PFS was 13 months. Of the 14 relapsed patients, 10 presented with distant metastases. Preoperative ECX is feasible and well tolerated. Although associated with a low pCR rate, survival with ECX was comparable with published studies suggesting that pCR may not correlate with satisfactory outcome from preoperative chemotherapy for localised oesophageal adenocarcinoma.
30 schema:genre article
31 schema:isAccessibleForFree true
32 schema:isPartOf N979d62e6de21466eb1f9105a2aa75665
33 Nf5322a3f28b2457c8abfa1207f7e2f50
34 sg:journal.1017082
35 schema:keywords ECX
36 EUS
37 II study
38 II trial
39 N1
40 OS
41 PFS
42 PS 0/1
43 Secondary end points
44 Simon
45 T3
46 adenocarcinoma
47 age 60 years
48 capecitabine
49 carcinoma
50 chemotherapy
51 cisplatin
52 cisplatin/capecitabine
53 cisplatin/fluorouracil
54 complete response rate
55 cycle
56 day of surgery
57 days
58 design
59 distant metastasis
60 early study termination
61 efficacy
62 end point
63 epirubicin
64 evaluable patients
65 fluorouracil
66 grade 3/4 toxicities
67 hand-foot syndrome
68 institutions
69 intent
70 junctional adenocarcinoma
71 males
72 median OS
73 median PFS
74 median age 60 years
75 metastasis
76 months
77 nausea/vomiting
78 neutropenia
79 oesophageal adenocarcinoma
80 oesophageal carcinoma
81 outcomes
82 pCR rate
83 pathological complete response rate
84 patients
85 phase II study
86 phase II trial
87 point
88 population
89 preoperative chemotherapy
90 primary end point
91 progression-free survival
92 rate
93 resection
94 response rate
95 safety
96 satisfactory outcome
97 stage II
98 statistical design
99 study
100 study termination
101 surgery
102 survival
103 survival rate
104 syndrome
105 termination
106 toxicity
107 treat population
108 treatment
109 trials
110 two-stage design
111 vomiting
112 years
113 schema:name A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma
114 schema:pagination 1725-1730
115 schema:productId N03a18cd788f04eefb0568f1595be29ec
116 N9fdf8c68f9f242caa13916e9694c73aa
117 Nc26f852f240a436cace7b932c18e9968
118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037816320
119 https://doi.org/10.1038/sj.bjc.6605070
120 schema:sdDatePublished 2022-10-01T06:35
121 schema:sdLicense https://scigraph.springernature.com/explorer/license/
122 schema:sdPublisher N0fa70c1f769f4bf6a678663029a0484e
123 schema:url https://doi.org/10.1038/sj.bjc.6605070
124 sgo:license sg:explorer/license/
125 sgo:sdDataset articles
126 rdf:type schema:ScholarlyArticle
127 N03a18cd788f04eefb0568f1595be29ec schema:name doi
128 schema:value 10.1038/sj.bjc.6605070
129 rdf:type schema:PropertyValue
130 N0c1b27e5a91543b0ab1a858ab077d394 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Aged
132 rdf:type schema:DefinedTerm
133 N0e51b467a5ff4f699ef12c2bdea5931a rdf:first sg:person.01000107664.44
134 rdf:rest Na47ec1fcf0fb41f8822413535bbfa9d2
135 N0fa70c1f769f4bf6a678663029a0484e schema:name Springer Nature - SN SciGraph project
136 rdf:type schema:Organization
137 N18ca7664e45544f7bd29db9584ed8078 rdf:first sg:person.01265153477.71
138 rdf:rest Neec861157b9e46289583e59525414c6c
139 N2108206adfb64d5897d9e15e89077740 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Fluorouracil
141 rdf:type schema:DefinedTerm
142 N2508ae81ae4a4b16b9e177873f8b71e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Follow-Up Studies
144 rdf:type schema:DefinedTerm
145 N2cc05ed3136e441591bf6b85ace5e0d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Adenocarcinoma
147 rdf:type schema:DefinedTerm
148 N2ddf383a56a0420a9d39bf4b53db79e7 rdf:first sg:person.01176653021.64
149 rdf:rest N0e51b467a5ff4f699ef12c2bdea5931a
150 N2f2792f5b0b94597b73925349a859447 rdf:first sg:person.01345371112.60
151 rdf:rest Nc1ddc759bb4846da85fd42daf49ab66a
152 N30f42e59786941d6a8a101c06738d1f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Survival Rate
154 rdf:type schema:DefinedTerm
155 N361a02bf89984625bf0a75a7635c07a0 rdf:first sg:person.011120523514.08
156 rdf:rest Ndc97afee1f644087a4d4b3ebab35e0e9
157 N36e2411d796b4cb4a5c97ca5fb8ea702 rdf:first sg:person.01136565472.17
158 rdf:rest N361a02bf89984625bf0a75a7635c07a0
159 N3cb7b3f6ed98467681cde4f98eb2634a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Humans
161 rdf:type schema:DefinedTerm
162 N48783759dd29455abd8c3a11f3eb0f4a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Capecitabine
164 rdf:type schema:DefinedTerm
165 N4959b325254b40d791def4d37e980165 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Epirubicin
167 rdf:type schema:DefinedTerm
168 N57e1416f04904026ba7026f728e01e5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Esophageal Neoplasms
170 rdf:type schema:DefinedTerm
171 N5c21635fd0324c67bedfe99de321573e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Antineoplastic Combined Chemotherapy Protocols
173 rdf:type schema:DefinedTerm
174 N6252b3982ba3487ca7d5c3ff7c4a396b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Middle Aged
176 rdf:type schema:DefinedTerm
177 N68690889e3474579b42e19add65e39dd rdf:first sg:person.0771664431.50
178 rdf:rest N18ca7664e45544f7bd29db9584ed8078
179 N6cc7c541206046dcbf6cc4596989e739 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Male
181 rdf:type schema:DefinedTerm
182 N7d42851743d64c5ab593aa71b602821d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Aged, 80 and over
184 rdf:type schema:DefinedTerm
185 N7e225bc7d6ca49c3b1c39061cb754e5b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Deoxycytidine
187 rdf:type schema:DefinedTerm
188 N84194ba192e44330bb7238cd3189684d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Combined Modality Therapy
190 rdf:type schema:DefinedTerm
191 N86c28f312af4473cac62de6d1cfed552 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Stomach Neoplasms
193 rdf:type schema:DefinedTerm
194 N87fd1a806c474eab97d4a487d632aeda rdf:first sg:person.01111010452.67
195 rdf:rest N2f2792f5b0b94597b73925349a859447
196 N920dd36ab3c7429497ee4083bd1492a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Female
198 rdf:type schema:DefinedTerm
199 N979d62e6de21466eb1f9105a2aa75665 schema:issueNumber 11
200 rdf:type schema:PublicationIssue
201 N9fdf8c68f9f242caa13916e9694c73aa schema:name dimensions_id
202 schema:value pub.1037816320
203 rdf:type schema:PropertyValue
204 Na47ec1fcf0fb41f8822413535bbfa9d2 rdf:first sg:person.01265070333.06
205 rdf:rest Nf82751b712b24568900763af66683eb1
206 Nbfaac87dac2348d9a9f3f22aec9a482d rdf:first sg:person.01035560774.45
207 rdf:rest rdf:nil
208 Nc1ddc759bb4846da85fd42daf49ab66a rdf:first sg:person.01270334576.91
209 rdf:rest Nbfaac87dac2348d9a9f3f22aec9a482d
210 Nc26f852f240a436cace7b932c18e9968 schema:name pubmed_id
211 schema:value 19436301
212 rdf:type schema:PropertyValue
213 Nd59bf7c57b17451292b9c0163f4aba50 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Disease Progression
215 rdf:type schema:DefinedTerm
216 Ndbbeffd489f44d3290b26b4481c52e98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
217 schema:name Adult
218 rdf:type schema:DefinedTerm
219 Ndc97afee1f644087a4d4b3ebab35e0e9 rdf:first sg:person.01320161130.16
220 rdf:rest N2ddf383a56a0420a9d39bf4b53db79e7
221 Ne424e6f2881c4acba0fbf11e503f9613 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
222 schema:name Cisplatin
223 rdf:type schema:DefinedTerm
224 Neec861157b9e46289583e59525414c6c rdf:first sg:person.01042675252.13
225 rdf:rest N87fd1a806c474eab97d4a487d632aeda
226 Nf5322a3f28b2457c8abfa1207f7e2f50 schema:volumeNumber 100
227 rdf:type schema:PublicationVolume
228 Nf82751b712b24568900763af66683eb1 rdf:first sg:person.0761075230.13
229 rdf:rest N68690889e3474579b42e19add65e39dd
230 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
231 schema:name Medical and Health Sciences
232 rdf:type schema:DefinedTerm
233 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
234 schema:name Oncology and Carcinogenesis
235 rdf:type schema:DefinedTerm
236 sg:journal.1017082 schema:issn 0007-0920
237 1532-1827
238 schema:name British Journal of Cancer
239 schema:publisher Springer Nature
240 rdf:type schema:Periodical
241 sg:person.01000107664.44 schema:affiliation grid-institutes:grid.5072.0
242 schema:familyName Wotherspoon
243 schema:givenName A
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000107664.44
245 rdf:type schema:Person
246 sg:person.01035560774.45 schema:affiliation grid-institutes:grid.5072.0
247 schema:familyName Chau
248 schema:givenName I
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035560774.45
250 rdf:type schema:Person
251 sg:person.01042675252.13 schema:affiliation grid-institutes:grid.5072.0
252 schema:familyName Riddell
253 schema:givenName A
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01042675252.13
255 rdf:type schema:Person
256 sg:person.01111010452.67 schema:affiliation grid-institutes:grid.5072.0
257 schema:familyName Stavridi
258 schema:givenName F
259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111010452.67
260 rdf:type schema:Person
261 sg:person.011120523514.08 schema:affiliation grid-institutes:grid.5072.0
262 schema:familyName Okines
263 schema:givenName A
264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011120523514.08
265 rdf:type schema:Person
266 sg:person.01136565472.17 schema:affiliation grid-institutes:grid.5072.0
267 schema:familyName Starling
268 schema:givenName N
269 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136565472.17
270 rdf:type schema:Person
271 sg:person.01176653021.64 schema:affiliation grid-institutes:grid.5072.0
272 schema:familyName Allum
273 schema:givenName W
274 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176653021.64
275 rdf:type schema:Person
276 sg:person.01265070333.06 schema:affiliation grid-institutes:grid.5072.0
277 schema:familyName Benson
278 schema:givenName M
279 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265070333.06
280 rdf:type schema:Person
281 sg:person.01265153477.71 schema:affiliation grid-institutes:grid.5072.0
282 schema:familyName Brown
283 schema:givenName G
284 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265153477.71
285 rdf:type schema:Person
286 sg:person.01270334576.91 schema:affiliation grid-institutes:grid.5072.0
287 schema:familyName Oates
288 schema:givenName J
289 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270334576.91
290 rdf:type schema:Person
291 sg:person.01320161130.16 schema:affiliation grid-institutes:grid.5072.0
292 schema:familyName Cunningham
293 schema:givenName D
294 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16
295 rdf:type schema:Person
296 sg:person.01345371112.60 schema:affiliation grid-institutes:grid.5072.0
297 schema:familyName Ashley
298 schema:givenName S
299 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01345371112.60
300 rdf:type schema:Person
301 sg:person.0761075230.13 schema:affiliation grid-institutes:grid.5072.0
302 schema:familyName Thompson
303 schema:givenName J
304 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761075230.13
305 rdf:type schema:Person
306 sg:person.0771664431.50 schema:affiliation grid-institutes:grid.5072.0
307 schema:familyName Thomas
308 schema:givenName J
309 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0771664431.50
310 rdf:type schema:Person
311 sg:pub.10.1038/sj.bjc.6600252 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051559904
312 https://doi.org/10.1038/sj.bjc.6600252
313 rdf:type schema:CreativeWork
314 sg:pub.10.1038/sj.bjc.6602572 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003250351
315 https://doi.org/10.1038/sj.bjc.6602572
316 rdf:type schema:CreativeWork
317 sg:pub.10.1186/1741-7015-2-35 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004336180
318 https://doi.org/10.1186/1741-7015-2-35
319 rdf:type schema:CreativeWork
320 grid-institutes:grid.5072.0 schema:alternateName Department of Computing and Statistics, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK
321 Department of Histopathology, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK
322 Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK
323 Department of Radiology, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK
324 Department of Surgery, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK
325 schema:name Department of Computing and Statistics, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK
326 Department of Histopathology, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK
327 Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK
328 Department of Radiology, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK
329 Department of Surgery, Royal Marsden Hospital NHS Foundation Trust, Surrey and London, UK
330 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...